{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Gomara MJ"],"funding":["Ministerio de Ciencia, Innovación y Universidades"],"pagination":["10654"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11477004"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["25(19)"],"pubmed_abstract":["With the aim of improving the uncertainties associated with the correct diagnosis of seronegative rheumatoid arthritis (RA) and identifying those at risk of developing interstitial lung disease (ILD), we have designed new peptide antigens bearing three post-translational modifications (PTMs) (citrulline, homocitrulline and acetyl-lysine) related to RA that could complement existing tests based on anti-citrullinated peptide/protein antibodies (ACPAs). Several chimeric peptides were synthesized and comparatively tested as antigens in ELISAs with two cohorts of sera: 178 RAs and 110 healthy blood donors. The results indicated that although chimeric peptides containing all three PTMs and vimentin and enolase domains do not significantly outperform existing ACPA tests in terms of sensitivity an"],"journal":["International journal of molecular sciences"],"pubmed_title":["Novel Chimeric Peptides Based on the Enolase Peptide Antigen (CEP-1) Bearing Three Post-Translational Modifications (Citrullination, Homocitrullination and Acetylation) for Determining the Diagnosis and Severity of Rheumatoid Arthritis."],"pmcid":["PMC11477004"],"funding_grant_id":["PID2021-122216OB-I00"],"pubmed_authors":["Gomez-Puerta JA","Sarmiento-Monroy JC","Haro I","Castellanos-Moreira R","Sanmarti R","Gomara MJ"],"additional_accession":[]},"is_claimable":false,"name":"Novel Chimeric Peptides Based on the Enolase Peptide Antigen (CEP-1) Bearing Three Post-Translational Modifications (Citrullination, Homocitrullination and Acetylation) for Determining the Diagnosis and Severity of Rheumatoid Arthritis.","description":"With the aim of improving the uncertainties associated with the correct diagnosis of seronegative rheumatoid arthritis (RA) and identifying those at risk of developing interstitial lung disease (ILD), we have designed new peptide antigens bearing three post-translational modifications (PTMs) (citrulline, homocitrulline and acetyl-lysine) related to RA that could complement existing tests based on anti-citrullinated peptide/protein antibodies (ACPAs). Several chimeric peptides were synthesized and comparatively tested as antigens in ELISAs with two cohorts of sera: 178 RAs and 110 healthy blood donors. The results indicated that although chimeric peptides containing all three PTMs and vimentin and enolase domains do not significantly outperform existing ACPA tests in terms of sensitivity an","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Oct","modification":"2025-04-04T00:34:03.571Z","creation":"2025-04-04T00:34:03.571Z"},"accession":"S-EPMC11477004","cross_references":{"pubmed":["39408982"],"doi":["10.3390/ijms251910654"]}}